Expert Ratings for Gilead Sciences
Over the past 3 months, 7 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts…
Gilead’s Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for
Kite, A Gilead Company, Announces Completion Of Marketing Authorization Transfer For Yescarta Car T-Cell Therapy In Japan
-- Gilead Sciences K.K. is Now Marketing Authorization Holder --
-- Kite Cell Therapy Business Unit of Gilead Sciences K.K. will manage the product's sales and promotion activities --
-- Kite's
Arcellx’s Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Gilead And Arcus Announced Anti-TIGIT Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
A Look Into Gilead Sciences’ Debt
Shares of Gilead Sciences Inc. (NASDAQ:GILD) decreased by 7.18% in the past three months. Before having a look…
Benzinga’s Top Ratings Upgrades, Downgrades For May 16, 2023
Upgrades According to Macquarie, the prior rating for Lufax Holding Ltd (NYSE:LU) was changed from Underperform to Outperform.…
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close at $23.49 on Monday.